U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H21F3N8O3S.ClH
Molecular Weight 546.954
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEFACTINIB HYDROCHLORIDE

SMILES

Cl.CNC(=O)C1=CC=C(NC2=NC=C(C(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=N2)C(F)(F)F)C=C1

InChI

InChIKey=RCHQNUQAHJNRBY-UHFFFAOYSA-N
InChI=1S/C20H21F3N8O3S.ClH/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34;/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C20H21F3N8O3S
Molecular Weight 510.493
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800029399 | https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=746096

Defactinib is an oral, investigational drug candidate for the treatment of various solid tumors. Through dual inhibition of FAK and PYK2, defactinib targets key resistance mechanisms in the tumor microenvironment (TME), including limited local immune response, dense stroma, and resident cancer stem cells, that may limit the effectiveness of current and investigational treatments. Treatment-related adverse events are: unconjugated hyperbilirubinemia, fatigue and headache.

Originator

Curator's Comment: # Pfizer

Approval Year

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas.
1995 Nov 7
Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer.
1996 Jan
Focal adhesion kinase and p53 signaling in cancer cells.
2007
The role of focal adhesion kinase in tumor initiation and progression.
2009 Oct-Dec
Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.
2011 Aug
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.
2013 Oct 2
Patents

Sample Use Guides

400 mg twice daily for 12, 21, or 35 days
Route of Administration: Oral
Defactinib produces potent in vitro inhibition of A431 epidermoid carcinoma cell-based FAK phosphorylation (IC50=3 nM).
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:46:44 GMT 2023
Edited
by admin
on Sat Dec 16 01:46:44 GMT 2023
Record UNII
L2S469LM49
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEFACTINIB HYDROCHLORIDE
USAN   WHO-DD  
USAN  
Official Name English
VS-6063 HYDROCHLORIDE
Code English
BENZAMIDE, N-METHYL-4-((4-(((3-(METHYL(METHYLSULFONYL)AMINO)-2-PYRAZINYL)METHYL)AMINO)-5-(TRIFLUOROMETHYL)-2-PYRIMIDINYL)AMINO)-, HYDROCHLORIDE (1:1)
Systematic Name English
N-Methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide monohydrochloride
Systematic Name English
N-METHYL-4-((4-(((3-METHYL(METHYLSULFONYL)AMINOPYRAZIN-2-YL)METHYL)AMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL)AMINO)BENZAMIDE HYDROCHLORIDE
Systematic Name English
N-METHYL-4-((4-(((3-METHYL(METHYLSULFONYL)AMINO)PYRAZIN-2-YL)METHYL)AMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL)AMINO)BENZAMIDE HYDROCHLORIDE
Systematic Name English
Defactinib hydrochloride [WHO-DD]
Common Name English
DEFACTINIB HYDROCHLORIDE [USAN]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/14/1429
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
FDA ORPHAN DRUG 393313
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
NCI_THESAURUS C1742
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
NCI_THESAURUS C1967
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
Code System Code Type Description
FDA UNII
L2S469LM49
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
PRIMARY
USAN
AB-93
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
PRIMARY
CAS
1073160-26-5
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
PRIMARY
PUBCHEM
25117347
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
PRIMARY
NCI_THESAURUS
C128039
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
PRIMARY
DRUG BANK
DBSALT002170
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
PRIMARY
SMS_ID
100000173904
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
PRIMARY
ChEMBL
CHEMBL3137331
Created by admin on Sat Dec 16 01:46:44 GMT 2023 , Edited by admin on Sat Dec 16 01:46:44 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY